Aguirre Blaise A. 4
4 · UNITED STATES ANTIMONY CORP · Filed Mar 30, 2026
Research Summary
AI-generated summary of this filing
United States Antimony (UAMY) Director Blaise Aguirre Sells Shares
What Happened Blaise A. Aguirre, a director of United States Antimony Corp (UAMY), reported three dispositions to the issuer (sales) totaling 31,712 shares for aggregate proceeds of $285,977. Transactions reported:
- 2026-03-24: 20,000 shares @ $9.16 = $183,200
- 2026-03-27: 6,339 shares @ $8.78 = $55,656
- 2026-03-27: 5,373 shares @ $8.77 = $47,121 These are sales/dispositions (coded D on the Form 4), not purchases or option exercises.
Key Details
- Transaction dates and prices: 3/24/2026 (20,000 @ $9.16), 3/27/2026 (6,339 @ $8.78; 5,373 @ $8.77).
- Total shares sold: 31,712; total proceeds: $285,977.
- Shares owned after transaction: not disclosed in the provided filing.
- Footnotes/plan info: filing lists "Disposition to the issuer (D)"; no 10b5-1 plan, tax-withholding explanation, or additional footnotes were provided in the summary information supplied.
- Filing date vs. trade dates: Form was filed 2026-03-30. The March 24 trade was reported several days after the transaction (reported March 30), while the March 27 trades were reported within a few business days. Filings for officers/directors are generally due within two business days of the transaction.
Context These transactions are sales (dispositions to the issuer) and do not represent purchases or option exercises. Sales by directors can be routine (e.g., portfolio management, tax/post-vest obligations) and do not, by themselves, indicate a change in company fundamentals. This summary is factual and does not speculate on motives.
Insider Transaction Report
Form 4
Aguirre Blaise A.
Director
Transactions
- Disposition to Issuer
Common Stock
2026-03-24$9.16/sh−20,000$183,200→ 884,466 total - Disposition to Issuer
Common Stock
2026-03-27$8.78/sh−6,339$55,656→ 878,127 total - Disposition to Issuer
Common Stock
2026-03-27$8.77/sh−5,373$47,121→ 872,754 total
Signature
/s/ Blaise Aguirre, MD|2026-03-30